prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumB, Final Pathologic Diagnosis: A. Sentinel lymph node #1, right axilla, biopsy: No tumor identified in one lymph. node (0/1). B. Non-sentinel lymph node #2, right axilla, biopsy: One lymph node positive for. metastatic carcinoma (1/1). C. Sentinel lymph node #2, right axilla, biopsy: No tumor identified in one lymph. node (0/1). D. Non-sentinel lymph node #1, right axilla, dissection: No tumor identified in one. lymph node (0/1). E. Non-sentinel lymph node #3, right axilla, dissection: Fibrofatty tissue, no tumor. or lymph node tissue seen on level sections. Working Draft. F. Right breast, lumpectomy: 1. Invasive ductal carcinoma, SBR grade II, 2.6 cm; see comment. 2. Lymphovascular invasion present. 3. Usual ductal hyperplasia. G. Lymph nodes, right axillary contents, dissection: No tumor identified in nineteen. lymph nodes (0/19). Note: Breast Tumor Synoptic Comment. - Laterality: Right. - Invasive tumor type: Invasive ductal carcinoma NOS. - Invasive tumor size: 2.6 cm maximum diameter (tumor spans slices 2-8, best seen in slides F4, F6,. F8, F10, F12, F13, and F15). - Invasive tumor grade (modified Bloom-Richardson): II. Nuclear grade: 2, 2 points. Mitotic count: 3 mitotic figures/10 HPF, 1 point. Tubule/papilla formation: Definite tubule formation in less than 10%, 3 points. Total points and overall grade = 6 points = grade 2. - Lymphatic-vascular invasion: Present (slide F15). - Resection margins for invasive tumor: - Deep margin: Negative; tumor is within less than 0.1 cm on slide F6 (black ink). - Medial margin: Negative. - Lateral margin: Negative. - Anterior/superior margin: Negative; tumor is within less than 0.1 cm on slide F10 (blue ink). Anterior/inferior margin: Negative; tumor is within 1 cm on slide F8 (green ink). - Ductal carcinoma in situ (DCIS) type: None identified. - Lobular carcinoma in situ (LCIS): None identified. - Lymph node status: - Number of positive lymph nodes: 1. - Total number sampled: 23. - Diameter of largest metastasis: 3 mm. - Extranodal extension: Absent. - AJCC/UICC stage: pT2N1MX. - Nontumorous breast tissue: Usual ductal hyperplasia. - Nipple: Unremarkable. - Skin/dermis: Unremarkable. Additional comments: ER, PR, and HER-2/neu stains have been ordered and will be reported in an. addendum. Intraoperative Consult Diagnosis. FS1 (A) Sentinel lymph node #1, right axilla, biopsy: One lymph node with no evidence of metastatic. carcinoma. (Dr. FS2 (B) Non-sentinel lymph node #2, right axilla, biopsy: Metastatic carcinoma. (Dr. FS3 (C) Sentinel lymph node #2, right axilla, biopsy: One lymph node with no evidence of metastatic. carcinoma. (Dr. Clinical History. The patient is a. year-old woman who undergoes a right breast lumpectomy with axillary lymph. node dissection. Gross Description. The specimen is received in seven parts, each labeled with the patient's name and unit number. Working Draft. Part A, labeled. consists of a single soft, irregular, red-tan. candidate lymph node measuring 1.2 X 0.6 x 0.4 cm. The entire specimen is frozen for frozen section. diagnosis 1, and subsequently submitted in cassette A1. Part B, labeled "non-sentinel lymph node #2 right axilla," consists of a single soft, irregular, red-tan. candidate lymph node measuring 1.3 X 0.8 x 0.5 cm. The entire specimen is frozen for frozen section. diagnosis 2, and subsequently submitted in cassette B1. Part C, labeled. consists of a single soft,. irregular piece of red-yellow, fatty tissue measuring 1.5 x 1 x 0.4 cm. Fatty tissue is trimmed away,. and a single candidate lymph node is found. The candidate fymph node is entirely submitted for. frozen section diagnosis 3, and subsequently submitted in cassette C1. The remaining unused fatty. tissue is entirely submitted in cassette C2. Part D, received in formalin and labeled. consists of one soft and firm,. tan-yellow, fatty tissue fragment measuring 1.7 x 1 x 0.4 cm. The entire specimen is submitted in. cassette D1. Part E, received in formalin and labeled. consists of one soft and firm,. tan-yellow, fatty tissue fragment measuring 1.6 x 1.2 x 0.4 cm. The entire specimen is submitted in. cassette E1. Part F is received in formalin and additionally labeled. It consists of a 9-gm. breast lumpectomy specimen, measuring 1.5 cm from anterior to posterior, 5 cm from superior to. inferior, and 3.5 cm from lateral to medial. There is a short stitch designated as superior and a long. stitch designated as lateral. The specimen is inked as follows: anterior superior blue, anterior inferior. green, and posterior black. Prior to receipt by me (Dr. the posterior portion of the. breast has been incised and tissue removed for tissue banking. The specimen is serially sectioned,. from medial to lateral, into eight slices and reveals a well-circumscribed, tan, firm nodule (1.5 x 1 x. 0.9 cm) in slices 3 through 6. The tumor nodule is located approximately 1 cm from both the lateral-. and medial-most margins, 0.7 cm from the superior margin, and 1.3 cm from the inferior margin. The. closest approach to a margin is in slice 6, where it appears to abut the anterior-mid portion of the. specimen (<1 mm grossly from the blue/green-inked margin). The specimen is entirely submitted as. follows: Cassette F1: Medial-most margin. Cassette F2: Slice 2, superior. Cassette F3: Slice 2, inferior. Cassette F4: Slice 3, superior (and nodule). Cassette F5: Slice 3, inferior. Cassette F6: Slice 4, superior (and nodule). Cassette F7: Slice 4, inferior. Cassette F8: Slice 5, superior (and nodule). Cassette F9: Stice 5, inferior. Cassette F10: Slice 6, superior (and nodule). Cassette F11: Slice 6, inferior. Cassette F12: Slice 7, superior. Cassette F13: Slice 7, inferior. Cassettes F14-F15: Lateral-most margin. Part G, received in formalin and labeled. consists of multiple soft and firm,. brown-tan and yellow tissue fragments measuring 7 x 6.5 x 1.5 cm in aggregate. The specimen is. trimmed and extensively searched for lymph nodes. Multiple candidate lymph nodes are found and. submitted intact in cassettes G1-G5. Fee Codes: Working Draft. Addenda. Addendum. Date Complete: Addendum Comment. An immunohistochemical test for estrogen and progesterone receptors was performed on block F6. The test for estrogen receptors is positive. There is strong nuclear staining in ~50% of tumor cells. The test for progesterone receptors is positive. There is weak to moderate nuclear staining in ~15%. of tumor cells. Result of HER2/neu test: This carcinoma is negative for HER2/neu oncoprotein over-expression. An immunohistochemical assay was performed on block F6 using the CB11 monocional antibody to. HER2/neu oncoprotein. The staining intensity of this carcinoma was 1 on a scale of 0-3. Carcinomas with staining intensity scores of 0 or 1 are considered negative for over-expression of HER2/neu oncoprotein. Those with a staining intensity score of 2 are considered indeterminate. We and others have observed that many carcinomas with. staining intensity scores of 2 do not show gene amplification. All carcinomas with staining intensity scores of 2 are therefore. submitted for FISH testing. The results of the FISH test are issued directly from the molecular cytogenetics laboratory. Carcinomas with staining intensity scores of 3 are considered positive for over-expression of HER2/neu oncoprotein. Tumors in. this category show an excellent correlation between the results of Immunohistochemical and FISH testing, and almost always show. gene amplification. The immunonerovirtase stain(s) reported above were developed and their performance characteristics determined by the. They have not been cleared or approved by the U. s. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should. not be regarded as Investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement. Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Other Specimens. Specimen Class: Accessioned. Specimen(s) Received: Left Breast, Fine Needle Aspiration. Final Diagnosis. Left Breast, Fine Needle Aspiration: Benign breast elements (see comment). Working Draft. Specimen Class: Accessioned. Specimen(s) Received: Vaginal/Cervical/Endocervical, Thin Prep Imaged. Final Diagnosis. Vaginal/Cervical/Endocervical, Thin Prep Imaged. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Atrophic changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned. Specimen(s) Received: Right Breast, Fine Needle Aspiration. Final Diagnosis. Right Breast, Fine Needle Aspiration: Adenocarcinoma, see note. Procedure/Addenda for. ADDENDUM. Date of Addendum.: Addendum Comment. An immunohistochemical test for estrogen and progesterone receptors as well as for HEr-2-neu was. performed on the material submitted for cell block. The test for estrogen receptors is positive There is strong nuclear staining in greater than 90% of. tumor cells. The test for progesterone receptors is Negative. There is no nuclear staining in 100% of tumor cells. Result of HER2/neu test: This carcinoma is negative for HER2/neu oncoprotein. over-expression on a scant specimen. Repeat testing is recommended on the excisional. specimen. An immunohistochemical assay was performed on the cell button using the CB11 monoclonal antibody. to HER2/neu oncoprotein. The staining intensity of this carcinoma was 1 on a scale of 0-3. Carcinomas with staining intensity scores of o or 1 are considered negative for over-expression of HER2/neu oncoprotein. Those with a staining intensity score of 2 are considered indeterminate. We and others have observed that many carcinomas with. staining Intensity scores of 2 do not show gene amplification. All carcinomas with staining intensity scores of 2 are therefore. submitted for FISH testing. The results of the FISH test are issued directly from the molecular cytogenetics laboratory. Carcinomas with staining intensity scores of 3 are considered positive for over-expression of HER2/neu oncoprotein. Tumors in. this category show an excellent correlation between the results of immunohistochemical and FISH testing, and almost always show. gene amplification. Working Draft. the stain(s) reborted above were developed and their performance charatteristies determined by the. They have not been cleared or approved by the U. S. Food and Drug Administrauon. FDA. has. determined. that. such. clearance or approval is not necessary. These tests are used for clinical purposes. They should. not be regarded as investigational or for research. This laboratory Is certified under the Clinical Laboratory Improvement. Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Specimen Class: Accessioned. Specimen(s) Received: Cervical/Endocervical, Direct. Final Diagnosis. Cervical/Endocervical, Direct. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Atrophic changes. SPECIMEN ADEQUACY: Satisfactory for evaluation; atrophic pattern with no identifiable. endocervical/transformation zone component. Cellular distortion secondary to airdrying artifact. Cellular distortion secondary to mechanical artifact. Specimen Class: Accessioned: Specimen(s) Received: A: 2:00 Right Breast, Fine Needle Aspiration, B: 5:00 Right Breast, Fine Needle Aspiration. Final Diagnosis. A. Right Breast, 2:00 o'clock, Fine Needle Aspiration: Lacatation changes; see comment. B. Right Breast, 5:00 o'clock, Fine Needle Aspiration: Lacatation changes; see comment. Specimen Class: Accessioned. Specimen(s) Received: Right breast core biopsy. Final Diagnosis. Right breast, needle core biopsy: Breast tissue with gestational lobular change and. suppurative inflammation; no in situ or invasive carcinoma seen. See comment. pecimen Class: Accessioned: Specimen(s) Received: Right Breast, Fine Needle Aspiration. Final Diagnosis. Right Breast. 2:00 o'clock, Fine Needle Aspiration: Atypical, see. note. Working Draft. Specimen Class: Accessioned: Specimen(s) Received: Vaginal/Cervical/Endocervical, Thin Prep. Final Diagnosis. Vaginal/Cervical/Endocervical, Thin Prep. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Specimen(s) Received: Uterine contents. Final Diagnosis. Uterine contents, evacuation: Decidua with chorionic villi. Specimen Class: Accessioned. Specimen(s) Received: Right Breast, Fine Needle Aspiration. Final Diagnosis. Right Breast, Fine Needle Aspiration: Lipoma; see comment. Specimen Class: Accessioned. Specimen(s) Received: Vaginal, Direct. Final Diagnosis. Vaginal, Direct. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. SPECIMEN ADEQUACY: Satisfactory for evaluation. Specimen Class: Accessioned: Specimen(s) Received: Vaginal/Cervical/Endocervical, Direct. Final Diagnosis. Vaginal/Cervical/Endocervical, Direct. CELLULAR CHANGES WITHIN NORMAL LIMITS. Working Draft. SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical cells present.

expanded version (tokens=3696) : 
 Main points from the breast pathology report are as follows:

Histological classification: 
- Invasive ductal carcinoma, subtype LumB
- No ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) identified

Necrosis: 
- No mention of necrosis

Tumor infiltrating lymphocytes: 
- No specific mention of tumor infiltrating lymphocytes

Histological grade:
- Modified Bloom-Richardson grade II (total points = 6, grade 2)
- Nuclear grade: 2 (2 points)
- Mitotic count: 3 mitotic figures/10 high power fields (1 point)
- Tubule/papilla formation: Definite tubule formation in less than 10% (3 points)

Lymphovascular invasion: 
- Present 

Calcification: 
- No mention of calcification

Receptor status:
- Estrogen receptor (ER): Positive (strong nuclear staining in ~50% of tumor cells)
- Progesterone receptor (PR): Positive (weak to moderate nuclear staining in ~15% of tumor cells)
- Human epidermal growth factor receptor-2 (HER2/neu) status: Negative for over-expression (staining intensity score 1, negative for gene amplification)

Ancillary testing results:
- No mention of any other ancillary testing results

Overall, the patient has invasive ductal carcinoma (LumB subtype) with a tumor size of 2

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=3844) : 
 Final Diagnosis: Invasive ductal carcinoma, LumB subtype, grade II. Size: 2.6 cm. Lymphovascular invasion present. Negative for necrosis and calcification. Estrogen receptor (ER) positive (strong staining in ~50% tumor cells). Progesterone receptor (PR) positive (weak to moderate staining in ~15% tumor cells). Negative for HER2/neu over-expression. No specific mention of tumor infiltrating lymphocytes or additional ancillary testing results.


